Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Joaquin Duato

AI came from tech, but the most advanced AI businesses are in every industry

Fortune’s AIQ 50 list of the most “mature” AI companies shows how different businesses are taking advantage of AI to meet their needs.

J&J CEO Slams Biden's Drug Pricing Law, Says It Will 'Chill' Innovation

J&J CEO Slams Biden's Drug Pricing Law, Says It Will 'Chill' Innovation

J&J CEO explained that the new drug-price negotiation law threatens development of new drugs, according to Bloomberg.

International Business Times

L’Oréal CEO explains why the 114-year-old beauty company spends a billion euro a year on tech—more than it invests in R&D

L’Oréal CEO explains why the 114-year-old beauty company spends a billion euro a year on tech—more than it invests in R&D

L'Oréal increasingly is capable of personalization, or as CEO Nicolas Hieronimus puts it, "beauty that's tailor-made" for each consumer.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Generative AI is top of mind for all types of leaders, from Treasury Secretary Janet Yellen to J&J CEO Joaquin Duato

This week’s episode of Fortune‘s Leadership Next podcast features conversations from the Fortune CEO Initiative conference.

In rare interview, J&J CEO Joaquin Duato opens up about Baby Powder cancer lawsuits and the future of Kenvue

J&J CEO Joaquin Duato's interview on Baby Powder cancer lawsuits, Kenvue, and the COVID vaccine.

The Strongest Pharma Stock This Week

Tighter bank lending and the Fed’s continued fight against inflation will likely push the economy into a recession this year. In this scenario, investors can look to invest in the pharma giant Johnson & Johnson (JNJ), given its financial strength, reliable dividend payments, and solid growth prospects. Read more….

1 Stock to Buy for Safety in This Volatile Market

With the Fed anticipating higher interest rate hikes than previously expected, the stock market is expected to remain volatile in the upcoming months. Given its strong balance sheet, brand recognition, and solid dividend payouts, it could be safe to invest in Johnson & Johnson (JNJ). Read more….

inkl

Read news from The Economist, FT, and more,
with one subscription

1 Dividend Stock to Buy Now and Retire on Later

1 Dividend Stock to Buy Now and Retire on Later

Johnson & Johnson (JNJ) continued its business momentum in the third quarter of fiscal 2022, driven by steady demand for its products and innovative, advancing portfolio and pipeline. Moreover, the company has a record of raising its dividend for 60 consecutive years. Amid the current uncertain market conditions, this fundamentally…

1 Stock That's Always a Safe Bet Amid Market Volatility

1 Stock That's Always a Safe Bet Amid Market Volatility

Leading healthcare company Johnson & Johnson (JNJ) has been able to navigate the volatile market conditions due to the defensive nature of its business and solid fundamentals. Moreover, the company has an impressive history of increasing its dividends. Given JNJ’s robust financials, high profitability, and consistent dividend payouts, we think…

1

People

Dipanjan BanchurSince

Mangeet Kaur BounsMangeet

Alyson Shontell

Nicolas Hieronimus

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Johnson & Johnson (

Medical – Pharmaceuticals

Leadership Next

Johnson Johnson JNJ

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

400,003 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play